Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 23

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 23
---
ed for one year unless a written notice of at least 180 days prior to the intended termination date is provided. The consideration
under each of the Lease and Services Agreements was US$9,000 per month after six months.

<div align='center'>9</div>

On January 21, 2025, the
Company entered into a Purchase Agreement with Genetics & IVF Institute, Inc. (“Purchase Agreement”), pursuant to
which the Company purchased all of the Assets (as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement)
relating to the MicroSort Business (as defined in the Purchase Agreement) from Genetics & IVF Institute, Inc. for a cash consideration
of $750,000 and a share consideration of 125,000 Class A Ordinary Shares (“Share Consideration” and equivalent to 2,500 Class
A Ordinary Shares after Third Reverse Stock Split). The Purchase Agreement is filed as Exhibit 10.30 of the Form F-1 registration statement
filed on May 29, 2025. MicroSort Lab Services, LLC (“MicroSort”) was incorporated by Genetics & IVF Institute, Inc.
in January 2025 to hold all of the Assets (as defined in the Purchase Agreement) to be transferred to the Company at closing. The Company’s
acquisition of MicroSort was completed on February 28, 2025, and the Share Consideration was issued to GIVF on the same day.

The flow chart below shows
the process involved in MicroSort:

Preimplantation Genetic Screening

PGS is used in parallel with
an IVF treatment cycle. PGS is the practice of determining the presence of aneuploidy (either too many or too few chromosomes) in a developing
embryo. PGS improves success rates of in vitro fertilization by ensuring the transfer of euploid embryos that have a higher chance of
implantation and resulting in a live birth. PGS has improved clinical outcomes for NewGenIvf by achieving a higher implantation rate
of 70.9% and reducing miscarriage rates by 26.6%.

Next-Generation Sequencing

NGS is a high-throughput
technology for determining the sequence of deoxyribonucleic acid DNA or RNA to study genetic variation associated with diseases or other
biological phenomena. NGS determines the sequence of a sample all at once by using parallel sequencing. Traditional Sanger sequencing
determines the sequence of a sample